AI Drug Repurposing Engine ReDrug Discovers Aspirin Can Effectively Suppress Triple-Negative Breast Cancer Spread
BenevolentAI's drug repurposing engine ReDrug discovers low-dose aspirin can reduce triple-negative breast cancer distant metastasis by 43% through inhibiting a specific platelet signaling pathway.
UK AI drug discovery company BenevolentAI announced a potentially groundbreaking finding on June 1, 2029: its AI drug repurposing engine ReDrug, after screening over 4,000 marketed drugs, discovered that low-dose aspirin can reduce triple-negative breast cancer distant metastasis by 43% through inhibiting the platelet GPVI signaling pathway.
Triple-negative breast cancer is the most aggressive breast cancer subtype, lacking effective targeted therapies, with a five-year survival rate of only about 12%. ReDrug identified this previously unknown connection by analyzing over 2 million medical literature articles and 1.5 million patient records.
BenevolentAI has partnered with Cancer Research UK to launch a Phase II clinical trial enrolling 600 triple-negative breast cancer patients. If successful, aspirin would become the first over-the-counter drug repurposed for cancer treatment, with monthly treatment costs under £10.
Disclaimer
Content is AI-generated. Do not use it as a basis for real decisions. Do not cite it as factual reporting.